Symposium 8 <subtitle>Role of IL-23 Inhibitors in PsA Management — Can It Be Considered Upfront?</subtitle> by Peter NASH

Get full text

Choosing the right treatment for patients with psoriatic arthritis by Maria Noviani, Marie Feletar, Peter Nash, Ying Ying Leung

Get full text

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib by Peter Nash, Stephen Hall, Paul Bird, Carol A Connell, Kenneth Kwok, David Witcombe, Krishan Thirunavukkarasu

Get full text

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposu... by Peter Nash, Hernan Valdez, Bruce E Sands, Thomas V Jones, Ann Madsen, Kim Papp, Huaming Tan

Get full text

What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? by Peter C. Taylor, Eugen Feist, Janet E. Pope, Peter Nash, Jean Sibilia, Roberto Caporali, Alejandro Balsa

Get full text

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data by Vivian P. Bykerk, Peter Nash, David Nicholls, Yoshiya Tanaka, Kevin Winthrop, Christina Popova, Nicola Tilt, Derek Haaland

Get full text

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2 by Atul Deodhar, Dafna Gladman, Rebecca Bolce, David Sandoval, So Young Park, Soyi Liu Leage, Peter Nash, Denis Poddubnyy

Get full text

Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis by Peter Nash, Ana-Maria Orbai, Tore K Kvien, Dafna Gladman, Chen-Yen Lin, Hitoshi Goto, Julie A Birt

Get full text

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized c... by Dafna D. Gladman, Peter Nash, Philip J. Mease, Oliver FitzGerald, Stephanie Duench, Mary Jane Cadatal, Karim R. Masri

Get full text

Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes by Peter Nash, James Cheng-Chung Wei, Federico Zazzetti, May Shawi, Jan P Dutz, Steve Peterson, Barkha P Patel, Kiefer Eaton

Get full text

Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison by Philip Mease, Ernest Choy, Peter Nash, Chrysostomos Kalyvas, Matthias Hunger, Luminita Pricop, Kunal K. Gandhi, Steffen M. Jugl, Howard Thom

Get full text

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison by Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B. McInnes

Get full text

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study by Alan J. Kivitz, Peter Nash, Hasan Tahir, Andrea Everding, Heřman Mann, Andrzej Kaszuba, Pascale Pellet, Albert Widmer, Luminita Pricop, Ken Abrams

Get full text

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study by Peter C. Taylor, Walid Fakhouri, Samuel Ogwu, Ewa Haladyj, Inmaculada de la Torre, Bruno Fautrel, Rieke Alten, Peter Nash, Eugen Feist

Get full text

P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a su... by Richard Furie, Peter Nash, Amit Saxena, Thomas Dörner, Subhashis Banerjee, Joan Merrill, Marilyn Pike, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison by Richard B. Warren, Iain B. McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J. Mease

Get full text

The diagnostic utility of diffusion weighted MRI imaging and ADC ratio to distinguish benign from malignant renal masses: sorting the kittens from the tigers by Suresh de Silva, Kathleen Rebecca Lockhart, Peter Aslan, Peter Nash, Anthony Hutton, David Malouf, Dominic Lee, Paul Cozzi, Fiona MacLean, James Thompson

Get full text

Differentiation of renal masses with multi-parametric MRI: the de Silva St George classification scheme by Suresh de Silva, Kathleen R. Lockhart, Peter Aslan, Peter Nash, Anthony Hutton, David Malouf, Dominic Lee, Paul Cozzi, Fiona MacLean, James Thompson

Get full text

Nutrient regulation by continuous feeding removes limitations on cell yield in the large-scale expansion of Mammalian cell spheroids. by Bradley P Weegman, Peter Nash, Alexandra L Carlson, Kristin J Voltzke, Zhaohui Geng, Marjan Jahani, Benjamin B Becker, Klearchos K Papas, Meri T Firpo

Get full text

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison by Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes

Get full text